ABO Blood Groups are Not Associated with Treatment Response and Prognosis in Patients with Local Advanced Non-Small Cell Lung Cancer

Unal, Dilek; Eroglu, Celalettin; Kurtul, Neslihan; Oguz, Arzu; Tasdemir, Arzu; Kaplan, Bunyamin

추천

검색

자료유형: 학술저널

저자정보: Unal, Dilek (Department of Radiation Oncology, Kayseri Education and Research Hospital) Eroglu, Celalettin (Department of Radiation Oncology, Erciyes University Medical School) Kurtul, Neslihan (Department of Radiation Oncology, Erciyes University Medical School) Oguz, Arzu (Department of Medical Oncology, Kayseri Education and Research Hospital) Tasdemir, Arzu (Department of Pathology, Kayseri Education and Research Hospital) Kaplan, Bunyamin (Department of Radiation Oncology, Erciyes University Medical School)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제6호

발행연도: 2013.1

수록면: 3,945 - 3,948 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Lung cancer is the leading cause of cancer death, late diagnosis being the main obstacle to improving the outcomes with stage at diagnosis as an important prognostic factor. Relationships between ABO blood groups and risk of benign or malignant diseases have been observed and in this study, we aimed to investigate whether they might affect prognosis and response to chemoradiotherapy in patients with local advanced non-small cell lung cancer (NSCLC). Materials and Methods: Eighty-one patients with non-metastatic local advanced NSCLC were included in the study. ABO blood groups were A in 45 (55.6%), B in 7 (8.6%), AB in 8 (9.9%), and O in 21 (25.9%) patients. The patients were also divided two groups according to blood group A (45 patients) and non-A (B, AB and O; 36 patients). Response to chemoradiotherapy was complete remission in 10 (12.3%), disease regression in 42 (51.9%), stable disease in 12 (14.8%), and disease progression in 17 (21.0%) patients. Results: There was no significant difference among ABO blood group categories or between patients with A blood group and those with non-A blood group in terms of responses to chemoradiotherapy (p>0.05). There were also no significant differences regarding overall and disease-free survival rates. Conclusion: The ABO blood group system has no significant effect on prognosis and response to chemoradiotherapy in patients with non-metastatic NSCLC.

#ABO blood groups #lung cancer #prognosis #response to chemoradiotherapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요